Skip to main content
Company profile
Os Therapies Incorporated logo

Os Therapies Incorporated

Pipeline6 assets

  • OST-HER2OST31-164 / HER2 / Bioengineered Listeria monocytogenes (Immunotherapy) / Oncology
    Osteosarcoma (Pulmonary Metastatic)Phase 2bActiveGlobalBreast CancerPhase 1ActiveGlobalCanine OsteosarcomaApprovedMarketedUS
  • OST-AXALAXAL / ADXS-HPV / HPV / Listeria-based Immunotherapy / Oncology
    HPV-associated cancersPhase 3ActiveGlobal
  • OST-503ADXS-503 / KRAS G12 position-related antigens / Listeria-based Immunotherapy / Oncology
    Non-Small Cell Lung Cancer (NSCLC)Phase 2ActiveGlobalGlioblastoma (GBM)Phase 2ActiveGlobalPancreatic CancerPreclinicalActiveGlobal
  • OST-504OST-PSA / ADXS-504 / ADXS31142 / PSA / Listeria-based Immunotherapy / Oncology
    Prostate Cancer (Castration-Resistant)Phase 1bActiveGlobal
  • OST-tADCVarious / Tunable Antibody-Drug Conjugate (ADC) / Oncology
    Ovarian CancerPreclinicalActiveGlobalBreast CancerPreclinicalActiveGlobal
  • OST-HOT constructsShared hotspot mutations and cancer-testes antigens / Listeria-based Immunotherapy / Oncology
    Solid TumorsPreclinicalActiveGlobal

Latest news25 items

All news
Os Therapies Incorporated • Endpoint Arena